Metabolic convergence of diabetes and prostate cancer: from dysglycemia to tumor microenvironment reprogramming
- 5 September 2026
- journal article
- research article
- Published by Springer Nature in Mammalian Genome
- Vol. 37 (1) , 105
Abstract
No abstract availableKeywords
This publication has 215 references indexed in Scilit:
- The GLP‐1 Receptor Agonist Liraglutide Promotes Anticancer Activities in MCF7 Breast and PC‐3 Prostate Cancer Cells by Modulating Glycolysis, Oxidative Stress and AdipokinesJournal of Biochemical and Molecular Toxicology, 2026
- Aggressive prostate cancer is associated with pericyte dysfunctionMolecular Oncology, 2025
- Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy ResultsJAMA Network Open, 2019
- Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta‐analysis of 11 cohort studiesDiabetes/Metabolism Research and Reviews, 2014
- Diabetes mellitus and risk of prostate cancer in the EuropeanProspectiveInvestigation into Cancer and NutritionInternational Journal of Cancer, 2014
- Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progressionInternational Journal of Cancer, 2014
- Circulating insulin‐like growth factor peptides and prostate cancer risk: A systematic review and meta‐analysisInternational Journal of Cancer, 2009
- Insulin analogues display IGF‐I‐like mitogenic and anti‐apoptotic activities in cultured cancer cellsDiabetes/Metabolism Research and Reviews, 2009
- Diabetes mellitus and risk of prostate cancer in the health professionals follow‐up studyInternational Journal of Cancer, 2008
- Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathwayThe Prostate, 2000